Prevalence of high-risk human papillomavirus DNA and mRNA and its association with abnormal anal cytology in the Czech male anal cancer screening cohort.
Adult
Anus Neoplasms
/ genetics
Czech Republic
DNA, Viral
/ genetics
Early Detection of Cancer
/ statistics & numerical data
Female
Homosexuality, Male
/ genetics
Humans
Male
Middle Aged
Papillomavirus Infections
/ epidemiology
Prevalence
RNA, Messenger
/ genetics
Sexual and Gender Minorities
/ statistics & numerical data
Young Adult
Czech MSM
anal cancer screening
anal cytology
high-risk human papillomavirus DNA
high-risk human papillomavirus mRNA
Journal
Diagnostic cytopathology
ISSN: 1097-0339
Titre abrégé: Diagn Cytopathol
Pays: United States
ID NLM: 8506895
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
24
08
2021
received:
14
07
2021
accepted:
28
08
2021
pubmed:
17
9
2021
medline:
8
2
2022
entrez:
16
9
2021
Statut:
ppublish
Résumé
Anal cancer (AC) screening is justified in high-risk populations, particularly HIV-positive men having sex with men (MSM). HR-HPV testing could improve the efficiency of cytologically based screening of AC, as in the screening of biologically analogical cervical cancer. The specificity of HR-HPV testing is influenced by the prevalence of HR-HPV infection in the screened population. Reported anal HR-HPV DNA prevalence in MSM is high, but HR-HPV mRNA reflects rather long-term infections and is more specific for high-grade lesions. However, no data were published about HR-HPV DNA and mRNA prevalence in the Czech AC screening population. Results of liquid-based anal cytology of 203 predominantly HIV-positive MSM from the Czech AC screening cohort were correlated with results of DNA and E6/E7 mRNA testing of 14 HR-HPV types, and HPV16 genotyping. Eighty-one MSM underwent a standard anoscopy. A total of 109 (53.7%) samples had abnormal cytology, with 12 (5.9%) ASC-H/HSIL, 67 (33.0%) samples cytologically negative, and 27 (13.3%) unsatisfactory. HR-HPV DNA was detected in 134 (66.0%) and HR-HPV RNA in 72 (35.5%) anal smears. HR-HPV mRNA and HPV16 mRNA positivity were associated with abnormal cytology (p = .0037, p = .0021). No significant association was found between HR-HPV DNA or HPV16 DNA positivity and abnormal cytology. No high-grade lesions were revealed by anoscopy. Prevalence of anal HR-HPV DNA among Czech MSM is high, however, the prevalence of HR-HPV mRNA is half and associated with abnormal cytology. Our results indicate an increased efficiency of cytological screening when combined with HR-HPV mRNA testing.
Sections du résumé
BACKGROUND
BACKGROUND
Anal cancer (AC) screening is justified in high-risk populations, particularly HIV-positive men having sex with men (MSM). HR-HPV testing could improve the efficiency of cytologically based screening of AC, as in the screening of biologically analogical cervical cancer. The specificity of HR-HPV testing is influenced by the prevalence of HR-HPV infection in the screened population. Reported anal HR-HPV DNA prevalence in MSM is high, but HR-HPV mRNA reflects rather long-term infections and is more specific for high-grade lesions. However, no data were published about HR-HPV DNA and mRNA prevalence in the Czech AC screening population.
METHOD
METHODS
Results of liquid-based anal cytology of 203 predominantly HIV-positive MSM from the Czech AC screening cohort were correlated with results of DNA and E6/E7 mRNA testing of 14 HR-HPV types, and HPV16 genotyping. Eighty-one MSM underwent a standard anoscopy.
RESULTS
RESULTS
A total of 109 (53.7%) samples had abnormal cytology, with 12 (5.9%) ASC-H/HSIL, 67 (33.0%) samples cytologically negative, and 27 (13.3%) unsatisfactory. HR-HPV DNA was detected in 134 (66.0%) and HR-HPV RNA in 72 (35.5%) anal smears. HR-HPV mRNA and HPV16 mRNA positivity were associated with abnormal cytology (p = .0037, p = .0021). No significant association was found between HR-HPV DNA or HPV16 DNA positivity and abnormal cytology. No high-grade lesions were revealed by anoscopy.
CONCLUSION
CONCLUSIONS
Prevalence of anal HR-HPV DNA among Czech MSM is high, however, the prevalence of HR-HPV mRNA is half and associated with abnormal cytology. Our results indicate an increased efficiency of cytological screening when combined with HR-HPV mRNA testing.
Substances chimiques
DNA, Viral
0
RNA, Messenger
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1188-1195Subventions
Organisme : Ministry of Health of the Czech Republic
ID : AZV17-31777A
Informations de copyright
© 2021 Wiley Periodicals LLC.
Références
Palefsky JM. Anal squamous intraepithelial lesions in human immunodeficiency virus-positive men and women. Semin Oncol. 2000;27:471-479.
Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis. 2012;54:1026-1034.
Palefsky JM. Anal squamous intraepithelial lesions: relation to HIV and human papillomavirus infection. J Acquir Immune Defic Syndr. 1999;21(Suppl 1):S42-S48.
Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127-1134.
Chen CC, Chou YY. Predictive value of the anal cytology for detecting anal intraepithelial neoplasia or worse: a systematic review and meta-analysis. Diagn Cytopathol. 2019;47:307-314.
Jin F, Roberts JM, Grulich AE, et al. The performance of human papillomavirus biomarkers in predicting anal high-grade squamous intraepithelial lesions in gay and bisexual men. AIDS. 2017;31:1303-1311.
Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103:368-383.
Weston G, Dombrowski C, Harvey MJ, et al. Use of the Aptima mRNA high-risk human papillomavirus (HR-HPV) assay compared to a DNA HR-HPV assay in the English cervical screening programme: a decision tree model based economic evaluation. BMJ Open. 2020;10:e031303.
Xu H, Lin A, Shao X, Shi W, Zhang Y, Yan W. Diagnostic accuracy of high-risk HPV genotyping in women with high-grade cervical lesions: evidence for improving the cervical cancer screening strategy in China. Oncotarget. 2016;7:83775-83783.
Schim van der Loeff MF, Mooij SH, Richel O, et al. HPV and anal cancer in HIV-infected individuals: a review. Curr HIV/AIDS Rep. 2014;11:250-262.
Arbyn M, Roelens J, Cuschieri K, et al. The APTIMA HPV assay versus the hybrid capture 2 test in triage of women with ASC-US or LSIL cervical cytology: a meta-analysis of the diagnostic accuracy. Int J Cancer. 2013;132:101-108.
Solomon D, Davey D, Kurman R, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287:2114-2119.
Clarke MA, Wentzensen N. Strategies for screening and early detection of anal cancers: a narrative and systematic review and meta-analysis of cytology, HPV testing, and other biomarkers. Cancer Cytopathol. 2018;126:447-460.
Siegenbeek van Heukelom ML, Marra E, de Vries HJC, et al. Risk factors for anal high-grade squamous intraepithelial lesions in HIV-positive MSM: is targeted screening possible? AIDS. 2017;31:2295-2301.
Albuquerque A, Rios E, Schmitt F. Recommendations favoring anal cytology as a method for anal cancer screening: a systematic review. Cancers (Basel). 2019;11:1942.
Wentzensen N, Follansbee S, Borgonovo S, et al. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. AIDS. 2012;26:2185-2192.
Schofield AM, Sadler L, Nelson L, et al. A prospective study of anal cancer screening in HIV-positive and negative MSM. AIDS. 2016;30:1375-1383.
Garbuglia AR, Gentile M, Del Nonno F, et al. An anal cancer screening program for MSM in Italy: prevalence of multiple HPV types and vaccine-targeted infections. J Clin Virol. 2015;72:49-54.
Todorova A, Schwierzeck V, Turek D, et al. Evaluation of anal carcinoma screening in male and female HIV patients at an interdisciplinary HIV therapy Centre. J Eur Acad Dermatol Venereol. 2019;33:1595-1601.
Templeton DJ, Roberts JM, Poynten IM, et al. Prevalence and predictors of unsatisfactory anal cytology tests in a cohort of gay and bisexual men in Sydney, Australia: baseline findings from the study of the prevention of anal cancer (SPANC). Eur J Cancer Prev. 2017;26:212-216.
Liu Y, Wang X, Kalir T, Chhieng D, Sigel K, Gaisa MM. Anal high-grade squamous intraepithelial lesions in human immunodeficiency virus-infected men: a study of 100 cases with emphasis on Cytohistologic correlation. Am J Clin Pathol. 2017;147:315-321.
Khattab R, McMeekin E, Taege AJ, et al. Unsatisfactory exfoliative anal cytology samples, 15-year experience with histologic, cytologic, and molecular follow-up. Diagn Cytopathol. 2018;46:117-121.
Rao R, Molina D, Halligan AM, Vakil B, Alperstein SA, Hoda RS. Negative computer-imaged ThinPrep pap test and positive hybrid capture2 HPV co-testing results: a quality assurance review. Diagn Cytopathol. 2015;43:763-769.
Lin C, Franceschi S, Clifford GM. Human papillomavirus types from infection to cancer in the anus, according to sex and HIV status: a systematic review and meta-analysis. Lancet Infect Dis. 2018;18:198-206.
Kreuter A, Potthoff A, Brockmeyer NH, et al. Anal carcinoma in human immunodeficiency virus-positive men: results of a prospective study from Germany. Br J Dermatol. 2010;162:1269-1277.
Szabó E, Kósa C, Babarczi E, et al. Prevalence of anal human papillomavirus infection in Hungarian men who have sex with men. Pathol Oncol Res. 2018;24:671-677.
Milosevic M, Poljak M, Mlakar B. Anal HPV infection in Slovenian men who have sex with men. Cent Eur J Med. 2010;5:698-703.
Tachezy R, Smahelova J, Salakova M, et al. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One. 2011;6:e21913.
Tachezy R, Jirasek T, Salakova M, et al. Human papillomavirus infection and tumours of the anal canal: correlation of histology, PCR detection in paraffin sections and serology. Apmis. 2007;115:195-203.
Iftner T, Neis KJ, Castanon A, et al. Longitudinal clinical performance of the RNA-based Aptima human papillomavirus (AHPV) assay in comparison to the DNA-based hybrid capture 2 HPV test in two consecutive screening rounds with a 6-year interval in Germany. J Clin Microbiol. 2019;57:e01177-18.
Pernot S, Boucheron P, Péré H, et al. Comparison of anal cancer screening strategies including standard anoscopy, anal cytology, and HPV genotyping in HIV-positive men who have sex with men. Br J Cancer. 2018;119:381-386.
Ong JJ, Walker S, Grulich A, et al. Incorporating digital anorectal examinations for anal cancer screening into routine HIV care for men who have sex with men living with HIV: a prospective cohort study. J Int AIDS Soc. 2018;21:e25192.